Skip to content

A study of the usefulness of Ninjinyoeito for hypotrophic patients

A study of the usefulness of Ninjinyoeito for hypotrophic patients with anorexia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031210674
Enrollment
20
Registered
2022-03-18
Start date
2022-05-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotrophic Hypotrophic

Interventions

arm Ninjinyoeito : Ninjinyoeito are orally administered 2 to 3 times a day for 12 weeks.

Sponsors

Asaoka Daisuke
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) 65 years old or older 2) Outpatients at our hospital who can walk on their own 3) Poor nutritional status with CONUT score more than mild and MNA less than 24 points 4) Anorexia who score 14 or below on the SNAQ 5) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Surgical resection of the stomach, gall bladder, small intestine, or large intestine except for appendicitis 2) Obese 3) Celiac disease, inflammatory bowel disease (Crohn's disease or ulcerative colitis), or ischemic colitis 4) Infectious enteritis 5) Mechanical obstruction, giant colon, or giant rectum 6) Malignant tumor of the digestive system except for cured by endoscopic surgery 7) Serious cardiovascular, respiratory, renal, hepatic, digestive, hematological, neurological, or psychiatric diseases except for sleeping pills only for insomnia. 8) Parkinson's disease 9) Hyperthyroidism or hypothyroidism 10) Participated in clinical trials, post-marketing clinical trials, or clinical research for other ethical drugs or medical devices within 3 months prior to obtaining consent. 11) Abusing alcohol and drugs 12) Allergy caused by herbal medicines, including Chinese herbal preparations 13) Regularly using other Chinese herbal preparations 14) Aldosteronism, myopathy, or hypokalemia 15) Inappropriate for participation in this study.

Design outcomes

Primary

MeasureTime frame
Amount of change in CONUT score from baseline at 12 weeks of treatment

Secondary

MeasureTime frame
1) Rate of change in CONUT 2) Amount of change in SNAQ 3) Amount of in GNRI 4) Amount of change in serum albumin 5) Amount of change in prealbumin 6) Amount of change in body weight 7) Amount of change in BMI 8) Amount of change in Izumo scale 9) Amount of change in EAT-10

Contacts

Public ContactDaisuke Asaoka

Juntendo Tokyo Koto Geriatric Medical Center

daisuke@juntendo.ac.jp+81-3-5632-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026